More about

Teprotumumab

News
April 04, 2022
1 min read
Save

Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease

IV methylprednisolone was linked to a small change in proptosis from baseline compared with placebo in patients with thyroid eye disease, while teprotumumab may improve proptosis and diplopia vs. IV methylprednisolone.

News
February 17, 2022
1 min watch
Save

VIDEO: Teprotumumab efficacy sustained after 6 months in thyroid eye disease

AUSTIN, Texas — In this Healio Video Perspective from the North American Neuro-Ophthalmology Society meeting, Prem Subramanian, MD, PhD, discusses the sustained efficacy of teprotumumab in patients with thyroid eye disease.

News
December 01, 2021
3 min watch
Save

VIDEO: 90% of patients in clinical trial adhere to teprotumumab

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Raymond Douglas, MD, PhD, discusses results of a clinical trial examining adherence to teprotumumab and reasons for nonadherence in patients with thyroid eye disease.

News
November 15, 2021
1 min read
Save

Teprotumumab may be effective in thyroid eye disease with less inflammation

NEW ORLEANS — Teprotumumab may offer comparable proptosis efficacy in patients with thyroid eye disease with low levels of inflammation as seen in patients with higher levels of inflammatory activity, according to a study.

News
October 27, 2021
3 min read
Save

Teprotumumab effective long term, during retreatment for thyroid eye disease

Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker.

News
October 27, 2021
2 min read
Save

Proposed guideline focuses on individualized approach for thyroid eye disease

Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers.

News
October 26, 2021
2 min read
Save

Treatment of thyroid eye disease varies between North American, European providers

First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker.

News
October 21, 2021
5 min read
Save

Year in review: Five studies changing thyroidology practice

In an update on notable, recently conducted thyroid studies, a speaker reviewed the latest treatments and imaging modalities for children and adults that have the potential to change thyroidology practice.

News
September 20, 2021
11 min read
Save

Thyroid eye disease requires joint management with ophthalmologists

Not everyone can agree on what to call thyroid eye disease. For some, it is thyroid-associated ophthalmopathy; for others, it is thyroid-related immune orbitopathy. It has also been referred to as Graves’ orbitopathy.

News
September 20, 2021
3 min read
Save

Should teprotumumab become first-line therapy for thyroid eye disease?

Traditionally, many experts in the field have advocated steroids. More recently, EUGOGO and others have advocated high-dose pulse steroid therapy in TED as that route of administration appears to be less associated with side effects.

View more